•  
  •  
  •  
  •  

2026-08-07 15:23:29

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  CDSCO

Stock Report

  • Kwality Pharmaceuticals Ltd receives CDSCO nod to Initiate Preclinical Pilot Batches of Pembroluzimab
  • CDSCO grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH®
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder
  • ZIM Laboratories Ltd receives approval from CDSCO - Directorate General of Health Services for Naproxen + Esomeprazole Capsules
  • AstraZeneca Pharma India Ltd receives sale and distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Durvalumab Solution
  • Biocon Limited gets approval for diabetes drug Liraglutide in India
  • Morepen to Launch Resmetirom - a New Drug for Fatty Liver
  • Wockhardt's yet another novel antibiotic Miqnaf™ receives favourable recommendation from Subject Expert Committee of CDSCO for the Treatment of CABP
  • Alkem Laboratories denies claims of Pan-D, Clavam 625 batches being not-of-standard quality
  • Torrent Pharmaceuticals Ltd refutes claims of Shelcal 500 allegedly failing CDSCO quality test
  • AstraZeneca Pharma India Ltd receives permission to import new drug
  • CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
  • AstraZeneca Pharma India Ltd receives permission from CDSCO to import new drug
  • Shilpa Medicare Limited Launches Lenvatinib Capsules (12mg, 18 mg and 24 mg) in India under the brand name Lenshil®
  • Tergene Biotech Pvt. Ltd receives SEC recommendation for pneumococcal 15 valent vaccine
  • AstraZeneca Pharma India receives permission for Dapagliflozin tablets
  • CoSara Diagnostics gets permission from CDSCO for SARAQ™ Hepatitis C Viral Load Kit as an IVD
  • Arrow Greentech's subsidiary successfully completes audit by FDCA and CDSCO
  • Shalby Ltd's subsidiary receives import license from CDSCO
  • Wockhardt gets CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines
  • Shilpa Medicare Ltd enters Phase I Clinical Trial for its New Biological Entity, recombinant Human Albumin

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025